Comparative Pharmacology
Head-to-head clinical analysis: AMIKIN versus GENTAK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKIN versus GENTAK.
AMIKIN vs GENTAK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
Gentamicin 3-5 mg/kg IV or IM once daily; alternatively, 1.5-2.5 mg/kg IV or IM every 8 hours.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
2–3 hours in adults with normal renal function; prolonged to 24–60 hours in severe renal impairment (CrCl <10 mL/min).
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
Renal excretion of unchanged drug accounts for >90% of elimination; <5% biliary/fecal.
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic